Upon engagement with its ligands, PD-L1 (CD274, B7-H1) and PD-L2 (CD273, B7-DC) expressed on tumor cells or APCs, PD-1 transduces inhibitory signals that dampen cytotoxic CD8+ T cell activation and contribute to tumor immune evasion in cancer [2]. Here, CD8A is linked to neoplasm.